Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : DD-CIA Due Diligence Central Intelligence Agency -- Ignore unavailable to you. Want to Upgrade?

To: R.C.L. who wrote (5)	6/29/1998 1:18:00 PM
From: PitBull	Respond to of 120

Bob there is an awesome amount of DD on the HABE thread as we both know, and it has grown so much, is there a way to make a cliff's notes version of all the highlights? I know you put a lot of information in your HABE post here, but if you get time, if you can somehow put it all together, that would be incredible. As you know, HABE is long term for me, and since I have been following it so closely, I regret that I haven't accumulated all the DD in one file, where someone new to HABE can read everything in importance in one sitting, and THEN have an efficient way to continue DD. Just a thought :) Marc on the HABE thread has made some good TA observations on the volume/price/strength/uptrend etc.

To: R.C.L. who wrote (5)	6/29/1998 6:25:00 PM
From: Jeffrey L. Henken	Read Replies (3) \| Respond to of 120

Thanks Bob for taken the time to bring HABE to our attention. I know you always do everything in your power to fully research your investments. HABE is of course a reporting company but perhaps not what we would call a fully reporting company. To date much like OZON they are running on future hopes. It was a long time between the 10K filed last year and the more recent 10Q. Here is the older but more thorough 10K which helps to explain some of the technology: sec.gov I know you have talked to the company's CEO Mr Haber yourself and that goes a long way to making any investor feel more secure about their company's future. Have you got any feel for when they might be able to make some inroads using ElectroMolecular Propulsion ("EMP") in chemical, biomedical and electronic fields? Do you feel secure that HABE can make money in this $10 billion industry. Can they do it soon? Lets take OZON for example. Wonderful technology especially on paper but even in the laundry field where the company has sold several systems sales have been slow. This with a technology that is reported to save as much as 66% in laundry costs over the long haul. The food business has yet to really materialize despite the Oct 1997 press release that read, " E coli solution close at hand." We both remember OZON at 3 3/4's and our hopes for much higher gains. I guess what I'm saying is that a company can have great technology and never really make it. Will that be the case with HABE or even OZON? I certainly hope not but it does take time. So what it looks like to me now is that HABE has right great technology but they need actual sales. Granted the opportunity for investors to benefit if the stock's profile is raised a bit does certainly exist. Looking back the highest I can find the stock trading with a quick check was .36 and that was not recently. Insider buying? I found none. Back in 1996 there was some insider selling at .25 and at .36. I guess I would have to say that until HABE starts announcing big contracts I would not get too greedy. That does not mean the stock will not move up far beyond those levels in anticipation of good things to come but if it does I would be surprised. Check out this chart on HABE and you will see that you are nicely extended above the 50 and 200 day moving averages. What will keep HABE heading higher? dailystocks.net Regards, Jeff

To: R.C.L. who wrote (5)	9/2/1998 9:20:00 AM
From: Jeffrey L. Henken	Respond to of 120

American BioMed, Inc. Names LaSalle St. Securities, Inc., Its Investment Banker THE WOODLANDS, Texas, Sept. 2 /PRNewswire/ -- American BioMed, Inc. (OTC Bulletin Board: ABMI - news) today announced it has selected Chicago based LaSalle St. Securities, Inc., as its investment banker. LaSalle St. will be providing long term strategic planning and identifying alternatives for securing financing. Michael Grady, Director of Corporate Finance of LaSalle St. Securities, Inc., stated, ''During our evaluation of American BioMed, we were pleased to discover that the company has such an extensive product line, significant proprietary technologies and broad patent coverage in the rapidly growing minimally invasive surgical device market. We are looking forward to assisting the company with its capital planning and assessing numerous opportunities to maximize the value of the company's intellectual property for its shareholders.'' Steven B. Rash, President & CEO of American BioMed, said, ''The Company will utilize LaSalle's considerable expertise in helping American BioMed attain greater visibility in the financial community, attract greater institutional participation in our stock and achieve our growth objectives. We hope to draw from LaSalle's extensive experience in dealing with emerging medical device companies and their intimate knowledge of the healthcare industry.'' LaSalle St. Securities is nationally recognized as a leading regional investment banking firm with branches in 10 states across the U.S., one in Germany and over 300 registered representatives. Founded in 1974, LaSalle St. Securities offers its clients the full range of services including merger and acquisition advice, public offerings of equity and debt, as well as private placements. Their services extend to a network of independent registered representatives, banks, savings & loans, credit unions, investment advisors and futures commission merchants. American BioMed, Inc. utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for the treatment of cardiovascular disease. The Company's products include 100%-silicone-based catheters through its Cathlab subsidiary; the Evert-O-Cath(TM), a toposcopic catheter for site-specific drug delivery and fluid removal; the OmniCath(R), an atherectomy catheter designed to remove atherosclerotic plaque from obstructed blood vessels throughout the body; and the OmniFilter, which is used to prevent blood clots and other detritus from reaching various organs of the body. The Company has over twenty-five patents and 11 FDA approvals covering its product portfolio, and addresses an annual worldwide market estimated to be in excess of $10 billion. ''Safe Harbor'' statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in the release are forward-looking statements that involve risks and uncertainties including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, the results of financing efforts, the effect of the Company's accounting policies, and other risks detailed in the Company's securities and Exchange Commission filings. SOURCE: American BioMed, Inc. biz.yahoo.com Regards, Jeff